Carregant...
Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
PURPOSE: Conivaptan is an intravenous dual V(1A)/V(2) vasopressin antagonist approved for the treatment of euvolemic and hypervolemic hyponatremia. Earlier studies showed that patients with moderate liver disease could be safely treated with conivaptan by reducing the dose by 50%, whereas patients w...
Guardat en:
| Publicat a: | Drug Des Devel Ther |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5315214/ https://ncbi.nlm.nih.gov/pubmed/28243060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S125459 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|